The Effects of Social Media Restriction on Social Anxiety, Fear of Missing Out, and Health-related Quality of Life: a Randomised Controlled Trial
NCT07929688, Not applicable, Not yet recruiting, University of Lausanne
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Effects of Social Media Restriction on Social Anxiety, Fear of Missing Out, and Health-related Quality of Life: a Randomised Controlled Trial | ClinicalTrials.gov |
| NCT number | NCT07929688 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 160 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Lausanne | ClinicalTrials.gov |
| Conditions | Social Media Users | ClinicalTrials.gov |
| Interventions | Social media restriction | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Liebowitz Social Anxiety Scale - Self-Report (LSAS-SR) | T1 (one week post-baseline) | The French version of the LSAS-SR will be used as the primary outcome to assess social anxiety. This scale includes 24 social situations, each rated for fear and avoidance on a four-point Likert scale scored from 0 to 3. A total score will be calculated (range 0-144), with a higher score indicating higher social anxiety. | ClinicalTrials.gov |
| Secondary | Liebowitz Social Anxiety Scale - Self-Report (LSAS-SR) | T2 (three-week post-baseline) | The French version of the LSAS-SR will be used as the primary outcome to assess social anxiety. This scale includes 24 social situations, each rated for fear and avoidance on a four-point Likert scale scored from 0 to 3. A total score will be calculated (range 0-144), with a higher score indicating higher social anxiety. | ClinicalTrials.gov |
| Secondary | Fear of Missing Out Scale (FoMOS) | T1 (one-week post-baseline) and T2 (three-week post-baseline) | The validated eight-item French version of the FoMOS will be used as a secondary outcome. Items are rated on a five-point Likert scale scored from 1 to 5. A sum score will be calculated (range 8-40), with a higher score indicating higher FoMO. | ClinicalTrials.gov |
| Secondary | Child Health Utility 9 Dimensions (CHU9D) | T1 (one-week post-baseline) and T2 (three-week post-baseline) | The CHU9D will be used as a secondary outcome to assess HRQoL. It comprises nine dimensions: worried, sad, pain, tired, annoyed, schoolwork/homework, sleep, daily routine, and able to join in activities, each with five severity levels. The schoolwork/homework item was reworded as "academic work/studies" to suit a student sample. Responses will be analysed as a continuous score and can be converted into a utility score anchored at 0 (dead) and 1 (full health). | ClinicalTrials.gov |
| Other | Social media use (safety outcome) | T1 (one-week post-baseline) and T2 (three-week post-baseline) | Social media use will be assessed using the Red Box, Green Box approach, a self-report behavioural frequency measure that has been developed for research into behavioural addictions. Changes in social media use will be used as a secondary safety outcome to assess the potential for a rebound effect. Participants will be asked to estimate the total number of hours they spend on social media in a typical week. The green box assesses leisure use, while the red box assesses use that displaces other activities. Higher scores indicate more frequent use. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)